CHChun-Tse Hung

Chun-Tse Hung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chun-Tse Hung has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Agreement Between ICD-10 Code–Only and Composite Definitions of Asthma Exacerbations in Electronic Health Records: A Multicenter Cohort Study in Taiwan, 2017-2023

    by Chun-Tse Hung, Chen-Yen An, Chi-Won Suk

    Background: Accurate identification of asthma exacerbations in electronic health records (EHRs) is essential for research and clinical decision-making. While composite definitions incorporating healthcare encounters and systemic corticosteroid use are commonly used, ICD-10 code-only definitions are often applied when detailed data are unavailable. However, their agreement remains unclear. This study aimed to (1) compare an ICD-10 code–only definition of asthma exacerbation with a composite definition, and (2) identify factors associated with concordance between both definitions in EHR data. Methods: We conducted a multicenter retrospective cohort study using the Taipei Medical University Clinical Research Database (2017– 2023). Asthma exacerbations were identified using (1) an ICD-10 code–only definition and (2) a composite definition incorporating asthma-related emergency department visits, hospitalization, or systemic corticosteroid use. Episodes were defined using a seven-day gap rule. Agreement was assessed using overall percent agreement (OPA), positive predictive value (PPV), negative predictive value (NPV), positive percent agreement (PPA), and negative percent agreement (NPA), with generalized estimating equations accounting for within-patient clustering. Results: Among 1,486,449 episodes, 40,180 (2.7%) met the code-only definition and 35,875 (2.4%) met the composite definition. After covariate adjustment, OPA was 0.930 (95% CI, 0.926– 0.933). PPV and PPA were 0.313 (95% CI, 0.293– 0.334) and 0.309 (95% CI: 0.291– 0.328), respectively, while NPV and NPA were high (0.968 and 0.962). Comorbidity burden, hospital, asthma severity, and index year were associated with concordance. Conclusion: ICD-10 code–only definition demonstrated high overall agreement with the composite definition, driven primarily by agreement on non-events, but limited agreement for identified exacerbations. These findings suggest that the two definitions may capture different levels of exacerbations. Several factors were associated with concordance between both definitions, highlighting the importance of accounting for these factors when analyzing EHR data. Code-only definitions may be used cautiously in EHR-based studies, given potential heterogeneity and misclassification.

  • Open Access

    Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study

    by Chun-Tse Hung, Chen-Yen An, Chi-Won Suk, Ting-Wei Lee, Shun-Hsing Hung

    Background: While glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promise in improving respiratory outcomes, the comparative effectiveness of dual glucose-dependent insulinotropic polypeptide/GLP-1 RA versus GLP-1 RA alone remains unclear. Objective: To assess the association of tirzepatide versus semaglutide with the risk of asthma exacerbation among patients with asthma and type 2 diabetes (T2D). Methods: Data from the TriNetX US Collaborative Network were used. Adults with asthma and T2D who initiated tirzepatide or semaglutide between June 01, 2022, and December 31, 2024, were included. The study period ended on December 1, 2025. The primary outcome was time to first asthma exacerbation over a 12-month follow-up. Secondary outcomes included systemic corticosteroid and short-acting beta-agonist (SABA) use. Propensity score matching was used to balance baseline covariates. Kaplan-Meier curves and Cox regression models were used to estimate comparative effectiveness. Results: After 1:1 matching, 8176 patients were included in each group. The risk of asthma exacerbation was similar between tirzepatide and semaglutide (11.0% vs 11.1%; HR, 1.00; 95% CI, 0.91– 1.10). This finding remained consistent across sensitivity and subgroup analyses. For secondary outcomes, tirzepatide was associated with a lower risk of SABA use (HR, 0.92; 95% CI, 0.88– 0.96) and a similar risk of systemic corticosteroid use (HR, 1.01; 95% CI, 0.96– 1.05) compared with semaglutide. Conclusion: Among patients with asthma and T2D, no difference in the risk of asthma exacerbation between tirzepatide and semaglutide was observed. Further investigation through randomized controlled trials is warranted to clarify the potential role of GLP-1 RA-based therapies in patients with asthma and T2D.

  • Antihyperglycemic Drugs and Risk of Asthma Exacerbation in Patients With Asthma and Type 2 Diabetes: A Multinational Retrospective Cohort Study

    by Chun‐Tse Hung, Chen‐Yen An, Yao‐Cheng Tsai, Chi‐Won Suk, Chung‐Hsuen Wu

    Background: Antihyperglycemic drugs have shown benefits in asthma control. However, evidence regarding the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2is) in reducing asthma exacerbations remains inconsistent. Objective: We aimed to evaluate the association of GLP‐1 RAs versus SGLT‐2is with risk of asthma exacerbation among patients with asthma and type 2 diabetes. Methods: This retrospective cohort study used electronic health record data from the TriNetX Global Collaborative Network. Adults with asthma and type 2 diabetes who initiated GLP‐1 RAs or SGLT‐2is between January 1, 2013, and June 30, 2024, were included. The primary outcome was the time to first asthma exacerbation. Secondary outcomes included first episode of asthma symptoms or systemic corticosteroid use. Patients were followed for up to 6 months in the main analysis. Propensity score matching was performed to balance baseline characteristics between groups. Cox proportional hazards models were used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). Results: A total of 100,746 patients were included, comprising 61,955 GLP‐1 RA users and 38,791 SGLT‐2i users. After 1:1 matching, both groups consisted of 28,831 patients. GLP‐1 RAs were associated with a decreased risk of asthma exacerbation compared with SGLT‐2is (HR, 0.88; 95% CI, 0.85–0.91). GLP‐1 RAs were also associated with a decreased risk of experiencing asthma symptoms (HR, 0.89; 95% CI, 0.82–0.97) and receiving systemic corticosteroids (HR, 0.79; 95% CI, 0.76–0.82). Results from sensitivity analyses were generally consistent, but the association for asthma exacerbation was not observed when follow‐up was extended to 1 year (HR, 0.95; 95% CI, 0.89–1.02). Conclusion: GLP‐1 RAs were associated with a decreased risk of asthma exacerbation compared to SGLT‐2is among patients with asthma and type 2 diabetes. As these findings reflect associations rather than causal effects, further investigation through randomized trials is warranted. image


  • Open Access

    Evaluating the association between omalizumab use and adverse fetal outcomes among pregnant women with asthma: a population-based retrospective cohort study

    by Chun-Tse Hung, Ting-An Yen, Hsin-Yi Huang, Chung-Hsuen Wu

    This study aimed to evaluate the association between omalizumab use during pregnancy and the risk of adverse fetal outcomes among pregnant women with asthma. This population-based retrospective cohort study was conducted using data from the 2010-2022 National Health Insurance Research Database and the Birth Certification Application in Taiwan. The study population was pregnant women with asthma. An active-comparator design was employed. Pregnant women who received at least one dose of omalizumab during pregnancy were assigned as the exposure group, while those having at least one prescription for inhaled corticosteroid (ICS) during pregnancy were assigned as the control group. The study outcome was adverse fetal outcomes. Propensity score matching was used to adjust for measurable confounders. Conditional logistic regression models were used to estimate the risk of adverse fetal outcomes. A total of 4,416 pregnant women with asthma were included, with 16 (0.1%) receiving omalizumab and 4,410 (99.9%) using ICS during pregnancy. The risk of adverse fetal outcomes, including pre-term birth (OR, 1.74; 95% CI, 0.46-6.63), low birth weight (OR, 1.04; 95% CI, 0.22-4.87), small for gestational age (OR, 1.11; 95% CI, 0.14-8.98), did not differ between omalizumab and ICS users. Omalizumab was not associated with an increased risk of adverse fetal outcomes among pregnant women with asthma. Further investigation with a larger sample of omalizumab users is warranted.

  • Association Between Asthma Biologics and Risk of Herpes Zoster Among US Adults With Asthma: A Pairwise Comparison

    by Chun‐Tse Hung, Chen‐Yen An, Jun Gong, Chi‐Won Suk, Yuarn‐Jang Lee, Shun‐Hsing Hung

    Summary: Real‐world evidence on herpes zoster risk across asthma biologics is limited. While most agents demonstrated comparable risks, omalizumab showed a higher risk than benralizumab and dupilumab.


  • Open Access

    Mirror, mirror on the wall: is CompEx the fairest endpoint of all?

    by Chun-Tse Hung, Steven R. Erickson, Chung-Hsuen Wu

    Preventing exacerbations is a key goal in asthma management [1]. Over the decades, novel asthma biologics have been approved to reduce the risk of exacerbation in patients with severe or uncontrolled asthma [1, 2]. Clinical trials have traditionally relied on severe exacerbation (SevEx) as the primary endpoint [3]. SevEx is typically defined as events that require systemic corticosteroids, asthma-related hospitalisations, or emergency department visits due to asthma requiring systemic corticosteroids [1, 3]. However, using SevEx as the sole endpoint may overlook subtler but impactful worsening events that patients experience daily [3]. Therefore, extending beyond SevEx as a single endpoint is important to facilitate the development of new therapies.